Breaking News

Charles River Laboratories Buys KWS BioTest for $20M

Bolsters the CRO’s immunology contract research services

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories has acquired KWS BioTest, a contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases, for roughly $20 million. KWS enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology. “The addition of KWS strategically expands Charles River...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters